Comparative Study of Cisplatin Combined With Gemcitabine and Paclitaxel in the Treatment of Recurrent Nasopharyngeal Carcinoma
Zhang Zhansheng1, Cao Jing2
1. Department of Oncology,Zhumadian Cancer Hospital,Zhumadian 463000,China; 2. Department of Radiotherapy,Zhumadian First people's Hospital,Zhumadian 463000,China
Abstract：Objective To investigate the comparative study of cisplatin combined with gemcitabine and paclitaxel in the treatment of recurrent nasopharyngeal carcinoma. Methods 85 patients with recurrent nasopharyngeal carcinoma treated in our hospital from July 2018 to March 2020 were selected as the research objects.According to the random number table method,they were divided into group A（42 cases）and group B（43 cases）.Group A received cisplatin + paclitaxel（TP）regimen,and group B received cisplatin + gemcitabine（GP）regimen.The short-term efficacy,tumor markers [platelet-derived growth factor（PDGF-BB）,serum epithelial cadherin（SE-CAD）] and toxicity reactions were observed in the two groups. Results The short-term efficacy of the two groups was compared（P>0.05）;after treatment,the levels of PDGF-BB and SE-CAD in the two groups were decreased,compared with those before treatment（P<0.05）;the levels of PDGF-BB and SE-CAD in the two groups after treatment were compared（P>0.05）;the gastrointestinal reaction in group B was lower than that in group A（P>0.05）. Conclusion GP and TP regimens have good efficacy in recurrent nasopharyngeal carcinoma,which can inhibit tumor growth.However,compared with TP Regimen,GP regimen has less gastrointestinal reaction and higher safety.
张战胜, 曹静. 顺铂分别联合吉西他滨及紫杉醇治疗复发性鼻咽癌对比研究[J]. 哈尔滨医药, 2021, 41(5): 16-18.
Zhang Zhansheng, Cao Jing. Comparative Study of Cisplatin Combined With Gemcitabine and Paclitaxel in the Treatment of Recurrent Nasopharyngeal Carcinoma. journal1, 2021, 41(5): 16-18.
2021, Vol. 41 
